The Zhitong Finance App learned that Novartis Pharmaceuticals (NVS.US) rose more than 5% to $160.82 on Tuesday. According to the news, Novartis said that tests showed that compared to patients treated with remibrutinib (remibrutinib) and patients treated with teriflunomide (teriflunomide), the recurrence rate and number of brain lesions were reduced, and no liver safety signals were observed.

The drug is expected to provide Novartis with a novel oral medication to treat multiple sclerosis and be the successor to its blockbuster Kesimpta series. This result has also further strengthened the market prospects for BTK inhibitors, which are designed to suppress harmful immune responses in diseases. Previously, similar drugs from Sanofi and Merck failed to outperform teriflomide in terms of recurrence rate indicators in later trials. The drug may also increase competition with Roche.

Novartis plans to submit a global marketing application for remibutinib to treat multiple sclerosis. Detailed results will be announced at a medical conference in Toronto later this year. The drug is currently approved in the US and Europe to treat chronic spontaneous urticaria, a skin condition characterized by recurrent bouts.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.